Waters Collaborates with Singapore’s Bioprocessing Technology Institute to Develop New Strategies to Identify Cancer Marker...
June 21 2016 - 5:12PM
Business Wire
Organizations Partner to Enhance the
Development of Analytical Methods and Glycan Libraries for Cancer
Glycobiology, Focusing on Glycosphingolipids
Waters Corporation (NYSE:WAT) today announced a joint effort
with the Bioprocessing Technology Institute (BTI), a research
institute within Singapore's Agency for Science, Technology and
Research (A*STAR), to develop new methods of finding cancer markers
and elucidating glycosylation pathways that could pave the way for
new therapeutic strategies.
As part of the research collaboration, Waters and BTI will
develop a glycosphingolipid (GSL) head group database containing
glucose unit (GU) retention times1 and collision cross-section
(CCS) values in an effort to compile an experimental library for
disease-related GSL glycans together with a glycan/MS spectral
library.
GSLs are highly complex structures in which glycan head groups
are attached to fatty acyl moieties. Analyzing their molecular
composition involves detailing the sequence, anomericity,
branching, and linkage positions of the oligosaccharides as well as
their fatty acyl motifs. GSLs are critical for cell growth,
interaction, and signaling and alterations to their structure may
result in diseases or promote the development of different types of
cancer. The analysis of the glycan head groups poses a particular
analytical challenge for glycoscience because isomeric structures
are not easily differentiated by either liquid chromatography (LC)
or mass spectrometry (MS) technologies when used alone.
“Collaborating with Waters will enable BTI to apply its
expertise in glycomics to develop analytical methods and a library
of information on GSLs that doesn’t yet exist today. This will
allow us to probe for potential clinical markers and to provide
insights into disease progression and regression following
therapeutic intervention. We anticipate our science will advance
human health while at the same time address some of the needs of
the biopharmaceutical industry,” said scientific lead Dr. Susanto
Woen, Research Scientist, BTI. “The partnership also allows us to
be part of an international glycomics research network pioneering
technologies required to determine the potential association
between GSL glycosylation and any phenotypic/genotypic traits in
disease or disease states.”
“By taking our partnership to a new level, we will empower BTI
to further develop novel analytical methods and establish a
comprehensive experimental glycan spectral library for cancer
glycobiology focusing on glycosphingolipids. Together, we want to
advance methods to study GSL glycosylation in cancer classification
and biomarker discovery,” said Dr. Jose Castro-Perez, Director –
Health Sciences Marketing, Waters Corporation.
As part of this collaboration, Waters will be contributing
scientific expertise and the use of a Waters® SYNAPT® G2-S High
Definition Mass Spectrometry® System. The instrument features ion
mobility mass spectrometry technology that rapidly separates
molecular ions by not only their size and mass-to-charge ratio, but
by their shape as well. A collisional cross-section (CCS) value is
a precise physicochemical property of an ion related to its size,
shape, and charge in the gas phase. The ability to determine the
separation of molecules based on a CCS value for each glycan head
group reveals insights into their unique chemical structure, which
in turn can be used as an additional descriptor for the GSL in
question, thus providing a higher degree of specificity than using
just mass-to-charge ratio alone.
First established in 2014, Waters’ collaborative relationship
with BTI initially focused on evaluating the performance of a new
N-linked glycan label aimed at biopharmaceutical applications, the
GlycoWorks™ RapiFluor-MS™ Glycan Kit, and its complete workflow –
from sample preparation to analysis – for glycosylation
profiling.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT) develops and manufactures advanced
analytical and material science technologies for laboratory
dependent organizations. For more than 50 years, the company has
pioneered a connected portfolio of separations science, laboratory
information management, mass spectrometry and thermal analysis
systems.
1. Albrecht, S.; Vainauskas, S.; Stockmann, H.; McManus, C.;
Taron, C. H.; Pauline M. Rudd, Anal. Chem.
DOI:10.1021/acs.analchem.6b00259.
Waters, SYNAPT, High-Definition Mass Spectrometry, GlycoWorks,
and RapiFluor-MS are trademarks of Waters Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160621006587/en/
Waters CorporationBrian J. Murphy, +1 508-482-2614Public
Relationsbrian_j_murphy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024